1. Scrip
  2. >>Therapy Areas

Daiichi Taps AnHeart As It Focuses Oncology Push

 
• By Ian Haydock

As part of its strategic pivot towards oncology, Daiichi Sankyo reaches a global out-licensing deal with a little-known US venture for an early-stage asset, which also hints at where its priorities lie.

two hands trying to connect couple puzzle piece with sunset background. Jigsaw alone wooden puzzle against sun rays. one part of whole. symbol of association and connection. business strategy.
Daiichi Oncology Strategy Coming Together • Source: Shutterstock

Japan's Daiichi Sankyo Co. Ltd. has licensed out its Phase I stage cancer drug DS-6051 globally to AnHeart Therapeutics, in the process signaling some honing of focus as part of its broader strategic push into oncology.

More from Anticancer

More from Therapy Areas

AbbVie On A STEAP Learning Curve In ADCs

 
• By Andrew McConaghie

Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By Kevin Grogan

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure

 
• By Alaric DeArment

The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.